Atlas Trials

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Clinical trial NCT05127486 · COMPLETED

Trial details

NCT number
NCT05127486
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
MigraineEpisodic Migraine
Start date
2021-12-06
Primary completion
2023-05-23
Enrollment
580

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.